by Gus Iversen
, Editor in Chief | June 14, 2021
From the June 2021 issue of HealthCare Business News magazine
The scanner, which is designed for both clinical and research use, features a 106-centimeter axial FoV that is four times the PET axial FoV of the company’s Biograph Vision 600," said John Khoury, the U.S. vice president of Molecular Imaging at Siemens Healthineers North America. "The new scanner has the same 3.2-millmeter silicon photomultiplier (SiPM) detector technology and Time of Flight (ToF) performance, and the extended FoV allows clinicians to image all the vital organs simultaneously with higher sensitivity."
“This has the axial field of view of four Vision 600s,” Khoury told HCB News. “What this means is that clinicians can now observe organ-to-organ interaction.”
Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576
The large FoV allows clinicians to examine patient anatomy during radiopharmaceutical uptake in shorter periods of time and allows for radiation oncology planning for larger patients, Khoury said. Scans, particularly for pediatric patients, can also be done faster and at a potentially lower radiation dose. It also has applications in therapy research.
In Europe, where the Biograph Vision Quadra is already approved and in use since receiving a CE Mark last fall, clinicians are using the scanner for high throughput images, cut from 20 minutes to three to five minutes.
Eckert & Ziegler to open new production facility for radiopharmaceutical development
In February, German medical isotope producer Eckert & Ziegler added a new Current Good Manufacturing Practices (cGMP) production facility in the U.S. for contract manufacturing of radiopharmaceuticals.
The cGMP clean room suite is an expansion of its production side in Wilmington, Massachusetts, and will be a 21 CFR 211 compliant, radiopharmaceutical manufacturing facility for late stage investigational and commercial stage radiopharmaceuticals. The aim behind its establishment is to provide radiopharmaceutical development services to companies searching for U.S. and worldwide contract manufacturing.
“At the moment, a large number of radiopharmaceutical substances from international pharmaceutical companies are in advanced clinical trials, some of them for broad indications such as prostate cancer,” said Dr. Lutz Helmke, member of the executive board of Eckert & Ziegler AG and responsible for its medical segment, in a statement. “With the new cGMP facility, we offer both regional and global pharmaceutical companies a one-stop service for a variety of radio-pharmaceutical services under cGMP conditions.”